328 related articles for article (PubMed ID: 37991544)
1. CRISPR/Cas9-mediated silencing of CD44: unveiling the role of hyaluronic acid-mediated interactions in cancer drug resistance.
Xu Z
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):2849-2876. PubMed ID: 37991544
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells.
Xiao Z; Wan J; Nur AA; Dou P; Mankin H; Liu T; Ouyang Z
Cell Physiol Biochem; 2018; 51(4):1879-1893. PubMed ID: 30504723
[TBL] [Abstract][Full Text] [Related]
3. The Hyaluronan/CD44 Axis: A Double-Edged Sword in Cancer.
Cirillo N
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958796
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
5. Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer.
Karousou E; Misra S; Ghatak S; Dobra K; Götte M; Vigetti D; Passi A; Karamanos NK; Skandalis SS
Matrix Biol; 2017 May; 59():3-22. PubMed ID: 27746219
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.
Liu T; Yan Z; Liu Y; Choy E; Hornicek FJ; Mankin H; Duan Z
Cell Physiol Biochem; 2018; 46(3):1218-1230. PubMed ID: 29672299
[TBL] [Abstract][Full Text] [Related]
7. Activation of Matrix Hyaluronan-Mediated CD44 Signaling, Epigenetic Regulation and Chemoresistance in Head and Neck Cancer Stem Cells.
Bourguignon LYW; Earle C; Shiina M
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837080
[TBL] [Abstract][Full Text] [Related]
8. CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.
Birzele F; Voss E; Nopora A; Honold K; Heil F; Lohmann S; Verheul H; Le Tourneau C; Delord JP; van Herpen C; Mahalingam D; Coveler AL; Meresse V; Weigand S; Runza V; Cannarile M
Clin Cancer Res; 2015 Jun; 21(12):2753-62. PubMed ID: 25762343
[TBL] [Abstract][Full Text] [Related]
9. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
11. The role of a new CD44st in increasing the invasion capability of the human breast cancer cell line MCF-7.
Fang XJ; Jiang H; Zhao XP; Jiang WM
BMC Cancer; 2011 Jul; 11():290. PubMed ID: 21749678
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells.
Bourguignon LY; Spevak CC; Wong G; Xia W; Gilad E
J Biol Chem; 2009 Sep; 284(39):26533-46. PubMed ID: 19633292
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression.
Bourguignon LY; Shiina M; Li JJ
Adv Cancer Res; 2014; 123():255-75. PubMed ID: 25081533
[TBL] [Abstract][Full Text] [Related]
14. CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer.
Hao JL; Cozzi PJ; Khatri A; Power CA; Li Y
Curr Cancer Drug Targets; 2010 May; 10(3):287-306. PubMed ID: 20370680
[TBL] [Abstract][Full Text] [Related]
15. Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance.
Wang SJ; Bourguignon LY
Am J Pathol; 2011 Mar; 178(3):956-63. PubMed ID: 21356346
[TBL] [Abstract][Full Text] [Related]
16. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.
Bjorklund CC; Baladandayuthapani V; Lin HY; Jones RJ; Kuiatse I; Wang H; Yang J; Shah JJ; Thomas SK; Wang M; Weber DM; Orlowski RZ
Leukemia; 2014 Feb; 28(2):373-83. PubMed ID: 23760401
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD44 DNA Aptamers Selectively Target Cancer Cells.
Pęcak A; Skalniak Ł; Pels K; Książek M; Madej M; Krzemień D; Malicki S; Władyka B; Dubin A; Holak TA; Dubin G
Nucleic Acid Ther; 2020 Oct; 30(5):289-298. PubMed ID: 32379519
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.
Jian YS; Chen CW; Lin CA; Yu HP; Lin HY; Liao MY; Wu SH; Lin YF; Lai PS
Int J Nanomedicine; 2017; 12():2315-2333. PubMed ID: 28392690
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer.
Wang SJ; Bourguignon LY
Arch Otolaryngol Head Neck Surg; 2006 Jul; 132(7):771-8. PubMed ID: 16847188
[TBL] [Abstract][Full Text] [Related]
20. Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells.
Yudovich D; Bäckström A; Schmiderer L; Žemaitis K; Subramaniam A; Larsson J
Sci Rep; 2020 Dec; 10(1):22393. PubMed ID: 33372184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
